After a milestone 2025, Hatteras Venture Partners is doubling down on a dual investment model – combining region-specific funds with a national strategy to drive early-stage innovation, capital continuity, and long-term growth in biotech, medtech, and healthtech.
Venture capital didn’t suddenly become disciplined—it just stopped rewarding the lack of it.
That shift is now reshaping how life sciences companies are built, and more importantly, who gets to build them. For firms optimized for speed and volume, the correction has been painful. For others, it looks more like a long-awaited alignment.
Hatteras Venture Partners falls squarely into the latter camp.
Coming off a milestone 2025—raising roughly $200 million, marking 25 years, and surpassing 100 portfolio companies—the firm isn’t framing its position as resilience. It’s operating as if the market has finally caught up to the way it has always invested.
This story is really about a broader reset in venture capital—and how a hybrid model of regional depth and national scale is emerging as a more durable blueprint for building life sciences companies.
The Venture Capital Reset: When Access Becomes the Constraint
For much of the past decade, venture capital had a defining advantage: speed. Capital moved quickly, deals closed faster, and the assumption was that access—to innovation, to founders, to opportunity—would naturally follow.
That assumption is breaking.
In today’s market, capital still exists, but access does not. Access to academic discovery. Access to translational science. Access to founders before they become competitive deals. The constraint has shifted upstream, closer to where companies are actually formed.
That shift is subtle, but it changes everything. It rewards firms that are embedded in the systems producing innovation—not just those positioned to fund it once it’s visible.
Building Companies at the Source, Not Chasing Them Later
Long before “emerging ecosystems” became a venture trend, Hatteras embedded itself in North Carolina’s Research Triangle—not as a satellite office, but as infrastructure.
Through region-specific funds, the firm has focused less on competing for deals and more on helping create them. Carolina Research Ventures accelerates UNC spinouts, while a WakeMed-affiliated fund integrates clinical insight directly into early-stage innovation. The Pisgah Fund extends that model into Western North Carolina, tying venture capital to economic development and healthcare access.
Taken together, these efforts reflect a deliberate strategy: generate proprietary deal flow by participating in the system that produces it.
This is upstream venture capital. And in a more disciplined market, it’s becoming a meaningful competitive advantage.
From Regional Roots to National Scale
While Hatteras’ foundation is regional, its strategy is not constrained by geography.
With Fund VII and its Opportunity Fund, the firm is investing across North America in biotech, medtech, and healthtech—extending its reach while maintaining its sourcing advantage. More importantly, it is evolving into a lifecycle investor, entering at the earliest stages and continuing to support companies through inflection points and into scale.
Because in today’s environment, access to a deal is rarely the limiting factor.
Staying in—and continuing to support it—is.
Capital Continuity Is Becoming the New Moat
One of the clearest lessons from the current venture cycle is that startups rarely fail because they can’t raise capital once. They fail because they can’t raise it consistently.
Hatteras’ model is designed to address that reality. Regional funds provide early access and conviction. A national fund expands reach and scale. An opportunity fund ensures follow-on capital is available when it matters most.
This isn’t just diversification—it’s infrastructure built for longer timelines, tighter markets, and a renewed emphasis on capital efficiency.
In this context, continuity becomes more than a feature. It becomes the moat.
The Southeast’s Gap—and Its Opportunity
Nowhere is this model more relevant than in the Southeast, where the ingredients for a thriving life sciences ecosystem are increasingly in place: strong academic institutions, growing founder migration, and expanding support infrastructure.
But the capital stack remains incomplete.
Access to large-check investors is still limited. Follow-on capital remains inconsistent. And that creates friction for companies trying to scale beyond early traction.
It also creates opportunity.
Firms like Hatteras are stepping into that gap as connectors—linking regionally generated innovation with national capital networks. In doing so, they are not just funding companies; they are helping complete the ecosystem itself.
This dynamic echoes broader trends across emerging hubs, including the BioHealth Capital Region and Greater Philadelphia, where capital, workforce, and infrastructure are still catching up to innovation.
Long-Term Outcomes Still Define Success
Even in a constrained market, breakout outcomes are still happening.
Hatteras’ role in the $2.25 billion exit of HistoSonics underscores what continues to matter: long-term commitment, scientific conviction, and the ability to stay invested through uncertainty. These were once overshadowed by speed and momentum. Now, they are being rewarded again.
And they align directly with the firm’s model.
What This Signals for Venture Capital’s Next Chapter
The next era of venture capital in life sciences will not be defined by geography alone—or by stage alone. It will be defined by integration: where companies are built, how they are funded, and who supports them across their lifecycle.
Hatteras’ dual strategy—build locally, invest nationally, and scale with continuity—reflects that shift. It also raises a broader question for the industry: if access is now the true constraint, then advantage will belong to those closest to it.
The firms best positioned for what comes next won’t be the fastest. They will be the most embedded, the most connected, and the most capable of supporting companies not just at entry—but all the way through.
Watch the full conversation:
https://www.youtube.com/watch?v=yhKxzUBDroY&list=PLnpdBqcUKPjmdIbKx54obuSTgKluNEdh7
